Combination of TATE and PD-1 Inhibitor in Liver Cancer
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Recruiting · NCT03259867 · Registry updated 2026-04-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combination of TATE and PD-1 Inhibitor in Liver Cancer | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Disease Progression, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric cancer, gastric neoplasm, hepatocellular carcinoma, liver disorder, neoplasm, stomach disorder | Recruiting | Phase 2 | 2026-04-16 | NCT03259867 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Teclison Ltd. | 3 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Medical College of Wisconsin | Milwaukee | United States | 483 |
| University of California, Irvine | Orange | United States | 29 |
| University of Oklahoma Health Science Center | Oklahoma City | United States | 7 |